Rouba Kozak
Neuropsychiatry Precision Medicine Lead Abbvie
Seminars
Thursday 17th September 2026
Panel Discussion: Redefining Therapeutic Potential in Muscarinics: Interrogating the M1/M4 Debate to Advance Next Generation Neuropsychiatric Treatments
3:00 pm
- What has Cobenfy taught us about the therapeutic potential of muscarinic mechanisms, and how should its success shape future drug development strategies?
- How should recent clinical readouts from selective M4 programs be interpreted, and what have they revealed about the opportunities and challenges of PAM-based approaches?
- To what extent do M1 and M4 receptor modulation contribute differently to efficacy, cognition, behavioural regulation and broader neuropsychiatric outcomes?
- How can developers address remaining translational challenges around dose selection, receptor occupancy, target engagement and biomarker development?
- Will M4 PAMs ultimately recapitulate the efficacy observed with M1/M4 agonist approaches, and what upcoming clinical readouts are most likely to answer this question?
- Looking ahead, where do muscarinic therapies have the greatest potential beyond schizophrenia, including psychosis associated with Alzheimer's disease and other neuropsychiatric disorders?
Thursday 17th September 2026
Harnessing Precision Neuropsychiatry: Integrating Biology, AI, and Big Data Beyond Muscarinic Targets
3:45 pm
- Bridging deep biological insight with AI-driven discovery to improve target identification and patient stratification
- Leveraging real-world data and multimodal datasets to refine clinical endpoints and predict treatment response
- Moving beyond muscarinic receptors to identify next-generation mechanisms for disease modification in psychiatry
- Translating precision medicine approaches into scalable R&D strategies for neuropsychiatric drug development
